Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 245.44 USD 2.75% Market Closed
Market Cap: 31.7B USD
Have any thoughts about
Alnylam Pharmaceuticals Inc?
Write Note

Wall Street
Price Targets

ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc

Wall Street analysts forecast ALNY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALNY is 308.81 USD with a low forecast of 179.78 USD and a high forecast of 420 USD.

Lowest
Price Target
179.78 USD
27% Downside
Average
Price Target
308.81 USD
26% Upside
Highest
Price Target
420 USD
71% Upside

ALNY Last Price Targets
Alnylam Pharmaceuticals Inc

The latest public price target was made on Oct 24, 2024 by Whitney Ijem from Canaccord Genuity , who expects ALNY stock to rise by 37% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Whitney Ijem
Canaccord Genuity
336 USD
Upside 37%
1 month ago
Oct 24, 2024
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
StreetInsider
Whitney Ijem
Canaccord Genuity
366 USD
Upside 49%
2 months ago
Oct 1, 2024
Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
StreetInsider
Tazeen Ahmad
Bank of America Securities
307 USD
Upside 25%
2 months ago
Sep 27, 2024
BofA Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
StreetInsider
Kostas Biliouris
BMO Capital
300 USD
Upside 22%
3 months ago
Aug 27, 2024
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
StreetInsider
Luca Issi
RBC Capital
300 USD
Upside 22%
3 months ago
Aug 26, 2024
RBC Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
StreetInsider
Salveen Richter
Goldman Sachs
370 USD
Upside 51%
4 months ago
Aug 16, 2024
Alnylam upgraded to Buy from Neutral at Goldman Sachs
TheFly
Whitney Ijem
Canaccord Genuity
357 USD
Upside 45%
5 months ago
Jul 8, 2024
Alnylam Pharmaceuticals (ALNY) PT Raised to $357 at Canaccord Genuity
StreetInsider
Esther Rajavelu
UBS
288 USD
Upside 17%
5 months ago
Jun 28, 2024
Alnylam Pharmaceuticals (ALNY) PT Raised to $288 at UBS
StreetInsider
Luca Issi
RBC Capital
265 USD
Upside 8%
5 months ago
Jun 27, 2024
Alnylam price target raised to $265 from $250 at RBC Capital
TheFly
Paul Matteis
Stifel Nicolaus
295 USD
Upside 20%
5 months ago
Jun 27, 2024
Alnylam Pharmaceuticals (ALNY) PT Raised to $295 at Stifel
StreetInsider
Luca Issi
RBC Capital
250 USD
Upside 2%
5 months ago
Jun 25, 2024
Alnylam price target raised to $250 from $235 at RBC Capital
TheFly
Liisa Bayko
Evercore ISI
260 USD
Upside 6%
5 months ago
Jun 25, 2024
Alnylam price target raised to $260 from $210 at Evercore ISI
TheFly
Patrick Trucchio
H.C. Wainwright
400 USD
Upside 63%
5 months ago
Jun 24, 2024
Alnylam HELIOS-B results support bull thesis, says H.C. Wainwright
TheFly
Paul Matteis
Stifel Nicolaus
247 USD
Upside 1%
5 months ago
Jun 24, 2024
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
StreetInsider
Andrew Galler
Morgan Stanley
250 USD
Upside 2%
5 months ago
Jun 24, 2024
Alnylam Pharmaceuticals (ALNY) PT Raised to $250 at Morgan Stanley
StreetInsider
Luca Issi
RBC Capital
235 USD
Downside 4%
6 months ago
Jun 12, 2024
RBC Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
StreetInsider
Kostas Biliouris
BMO Capital
234 USD
Downside 5%
8 months ago
Apr 8, 2024
BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
StreetInsider
Show More Price Targets
Show Less Price Targets
Whitney Ijem
Canaccord Genuity
Price Target 336 USD
Upside/Downside 37%
View Source
Whitney Ijem
Canaccord Genuity
Price Target 366 USD
Upside/Downside 49%
View Source
Tazeen Ahmad
Bank of America Securities
Price Target 307 USD
Upside/Downside 25%
View Source
Kostas Biliouris
BMO Capital
Price Target 300 USD
Upside/Downside 22%
View Source
Luca Issi
RBC Capital
Price Target 300 USD
Upside/Downside 22%
View Source
Salveen Richter
Goldman Sachs
Price Target 370 USD
Upside/Downside 51%
View Source
Whitney Ijem
Canaccord Genuity
Price Target 357 USD
Upside/Downside 45%
View Source
Esther Rajavelu
UBS
Price Target 288 USD
Upside/Downside 17%
View Source
Luca Issi
RBC Capital
Price Target 265 USD
Upside/Downside 8%
View Source
Paul Matteis
Stifel Nicolaus
Price Target 295 USD
Upside/Downside 20%
View Source
Luca Issi
RBC Capital
Price Target 250 USD
Upside/Downside 2%
View Source
Liisa Bayko
Evercore ISI
Price Target 260 USD
Upside/Downside 6%
View Source
Patrick Trucchio
H.C. Wainwright
Price Target 400 USD
Upside/Downside 63%
View Source
Paul Matteis
Stifel Nicolaus
Price Target 247 USD
Upside/Downside 1%
View Source
Andrew Galler
Morgan Stanley
Price Target 250 USD
Upside/Downside 2%
View Source
Luca Issi
RBC Capital
Price Target 235 USD
Upside/Downside 4%
View Source
Kostas Biliouris
BMO Capital
Price Target 234 USD
Upside/Downside 5%
View Source
Show More Price Targets
Show Less Price Targets
Alnylam Pharmaceuticals Inc Competitors:
Price Targets
ACHV
Achieve Life Sciences Inc
342% Upside
RXRX
Recursion Pharmaceuticals Inc
67% Upside
301207
Hualan Biological Bacterin Inc
62% Upside
MDXG
MiMedx Group Inc
41% Upside
ORGO
Organogenesis Holdings Inc
57% Upside
CTMX
CytomX Therapeutics Inc
395% Upside
FYB
Formycon AG
80% Upside
MNKD
MannKind Corp
33% Upside

Revenue
Forecast

Revenue Estimate
Alnylam Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Alnylam Pharmaceuticals Inc's revenue is 61%. The projected CAGR for the next 4 years is 25%.

61%
Past Growth
25%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Alnylam Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Alnylam Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ALNY's stock price target?
Price Target
308.81 USD

According to Wall Street analysts, the average 1-year price target for ALNY is 308.81 USD with a low forecast of 179.78 USD and a high forecast of 420 USD.

What is Alnylam Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
25%

For the last 8 years the compound annual growth rate for Alnylam Pharmaceuticals Inc's revenue is 61%. The projected CAGR for the next 4 years is 25%.

Back to Top